During the last session, Fate Therapeutics Inc (NASDAQ:FATE)’s traded shares were 2.04 million, with the beta value of the company hitting 1.77. At the end of the trading day, the stock’s price was $4.30, reflecting an intraday loss of -5.29% or -$0.24. The 52-week high for the FATE share is $8.83, that puts it down -105.35 from that peak though still a striking 62.09% gain since the share price plummeted to a 52-week low of $1.63. The company’s market capitalization is $489.43M, and the average trade volume was 2.78 million shares over the past three months.
Fate Therapeutics Inc (NASDAQ:FATE) trade information
Fate Therapeutics Inc (FATE) registered a -5.29% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.29% in intraday trading to $4.30, hitting a weekly high. The stock’s 5-day price performance is -18.41%, and it has moved by -37.41% in 30 days. Based on these gigs, the overall price performance for the year is -32.18%.
Fate Therapeutics Inc (FATE) estimates and forecasts
Statistics show that Fate Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Fate Therapeutics Inc (FATE) shares have gone up 138.89% during the last six months, with a year-to-date growth rate less than the industry average at -18.29% against 12.90. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -157.90% this quarter and then jump 9.30% in the quarter after that. In the rating firms’ projections, revenue will decrease -93.60% compared to the previous financial year.
Revenue for the current quarter is expected to be $1.11 million as predicted by 14 analyst(s). Meanwhile, a consensus of 14 analyst(s) estimates revenue growth to $1.13 million by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $58.98 million and $5.53 million respectively. In this case, analysts expect current quarter sales to shrink by -98.10% and then drop by -79.60% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -6.65%. While earnings are projected to return -17.52% in 2024.
FATE Dividends
Fate Therapeutics Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
